Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
V. Dembitz, H. Lawson, R. Burt, C. Philippe, S. C. James, S. Atkinson, J. Durko, L. M. Wang, J. Campos, A. M. Magee, K. Woodley, M. J. Austin, A. Rio-Machin, P. Casado-Izquierdo, F. Bewicke-Copley, , P. Gallipoli
SCD inhibition induces AML cell death and synergizes with chemotherapy to prolong survival in murine AML models.
bioRxiv · Aug 2, 2023Cancer Biology
E. Griessinger, D. Pereira-Martins, M. Nebout, C. Bosc, E. Saland, E. Boet, A. Sahal, J. Chiche, D. Debayle, L. Fleuriot, M. Pruis, V. De Mas, F. Vergez, C. Recher, G. Huls, , J.-F. Peyron
The paper identifies cold sensitivity as a vulnerability in FAO-supported OxPhos leukemic stem cells, which can be exploited for therapeutic targeting.
bioRxiv · Apr 17, 2023 · PreprintCancer Biology
D. A. Pereira-Martins, J. Hilberink, I. Weinhauser, E. Rego, G. Huls, J. J. Schuringa
The paper examines how thiostrepton affects tumor-associated macrophages, exploring its potential to shift their polarization from M2 to M1.
bioRxiv · Mar 23, 2023 · PreprintCancer Biology
K. Lima, D. A. Pereira-Martins, L. B. L. de Miranda, J. L. Coelho-Silva, G. d. S. Leandro, I. Weinhauser, R. d. C. Cavaglieri, A. M. de Leal, W. F. da Silva, A. P. A. d. L. Lange, E. D. R. P. Velloso, E. Griessinger, J. R. Hilberink, G. Huls, J. J. Schuringa, , J. A. Machado-Neto
This study shows that THZ-P1-2, a PIP4K2 inhibitor, kills leukemia cells by disrupting mitochondrial homeostasis and autophagy, with minimal effects on healthy cells.
bioRxiv · Aug 20, 2022Pharmacology & Toxicology
I. Weinhauser, D. Pereira-Martins, L. Almeida, J. Hilberink, C. Ortiz, D. Silveira, L. Quek, C. Araujo, T. Bianco, A. Lucena-Araujo, N. Visser, S. Hogeling, A. Diepstra, E. Ammatuna, G. Huls, , J. J. Schuringa
The paper shows M2-polarized macrophages promote leukemia stem cell survival by enhancing stemness, homing, immune evasion, and metabolic reprogramming.
bioRxiv · May 6, 2022Cancer Biology
N. Vilaplana-Lopera, R. Almaghrabi, G. Papatzikas, V. Cuminetti, E. Gonzalez, M. Jeeves, A. Cunningham, A. Erdem, F. Schnuetgen, M. Raghavan, S. Potluri, J.-B. Cazier, J. J. Schuringa, M. A. Reed, L. Arranz, , P. Garcia
The paper identifies a metabolic crosstalk between AML and stromal cells where AML cells induce stromal cells to secrete acetate for their own energy needs.
bioRxiv · Jan 21, 2021Cell Biology
H. Maat, J. Jaques, A. Rodriguez Lopez, S. Hogeling, M. P. de Vries, C. Gravesteijn, A. Brouwers-Vos, G. Huls, E. Vellenga, V. van den Boom, J. J. Schuringa
This study identifies USP7 as a therapeutic target in leukemia, particularly in TP53-mutated AML, by showing its role in non-canonical PRC1.1 complex stability and function.
bioRxiv · Jul 9, 2019Cancer Biology
H. Maat, J. Jaques, E. Vellenga, G. Huls, V. Schuringa, J. J. Schuringa
This study uses a lentiviral vector to inducibly knock down PCGF1 in human leukemia models, showing that timing of gene repression affects treatment efficacy and clonal drift in leukemic stem cells.
bioRxiv · Jul 8, 2019 · PreprintCancer Biology